A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4110-4110
Author(s):  
A. Santoro ◽  
V. Andretta ◽  
V. Gregorc ◽  
L. Rimassa ◽  
E. Bennicelli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Single Agent ◽  
Vascular Targeting ◽  
Vascular Targeting Agent

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

2010 ◽  
Vol 46 (15) ◽  
pp. 2746-2752 ◽  
Author(s):  
Armando Santoro ◽  
Lorenza Rimassa ◽  
Alberto F. Sobrero ◽  
Giovanni Citterio ◽  
Francesco Sclafani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Standard Therapy ◽  
Phase Ii Study ◽  
Vascular Targeting ◽  
Vascular Targeting Agent

scholarly journals First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Tetsuji Terazawa ◽  
Takeshi Kato ◽  
Masahiro Goto ◽  
Daisuke Sakai ◽  
Yukinori Kurokawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Elderly Patients ◽  
Phase Ii ◽  
Study Protocol ◽  
Frail Elderly ◽  
Phase Ii Study ◽  
Single Agent ◽  
Wild Type ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document